CVRx Stock

CVRx Current Assets

The Current Assets of CVRx (CVRX) as of Sep 11, 2026 is 90.98 M USD. In the previous year, Current Assets was 129.81 M USD — a change of -29.91% (lower).

Current Assets

90.98 MUSD

YoY

-29.91%

Last updated:

Current Assets of CVRx is 2026 90.98 M USD. Current Assets of CVRx was 2025 129.81 M USD. It decreases by -29.91% lower compared to the previous year.

The CVRx Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
28.89 M USD
Jan 1, 2020
64.36 M USD
Jan 1, 2021
151.14 M USD
Jan 1, 2022
122.87 M USD
Jan 1, 2023
112.09 M USD
Jan 1, 2024
129.81 M USD
Jan 1, 2025
90.98 M USD
The CVRx Current Assets history
YEARCurrent AssetsYoY
90.98 MUSD-29.91%
129.81 MUSD+15.81%
112.09 MUSD-8.78%
122.87 MUSD-18.70%
151.14 MUSD+134.83%
64.36 MUSD+122.79%
28.89 MUSD
Access this data via the Eulerpool API

CVRx Stock analysis

What does CVRx do? CVRx Inc is a medical technology company that is revolutionizing the global market for treatment-resistant hypertension patients with its innovative "Baroreflex Activation Therapy" (BAT) system. The company was founded in 2001 and has its headquarters, development, manufacturing, and distribution facility in Minneapolis, Minnesota. With its innovative products and medical expertise, the company aims to become a global leader in medical research and development of apps and medical devices. The company was founded by Dr. Robert Kieval and his partner in medical research, Dr. Casey Cunningham. Together, they identified a potential treatment gap for patients who were unresponsive to existing methods or unable to receive appropriate therapy due to comorbidities. They decided to develop a novel technology that activates the body's natural regulatory system, the baroreflex system. With a clinical expert team in Minneapolis, they developed an implantable device connected to specific pressure zones in the neck through an electrode. The device artificially stimulates the baroreflex and regulates the blood pressure system. After many years of clinical tests and studies, the company received FDA approval in 2019. The company is now publicly listed, and its products are available worldwide. CVRx's business model is based on the research, development, production, and marketing of innovative medical devices and technologies. The focus is on improving patients' quality of life and advancing medical research. The products and therapies are distributed globally through contractual partners and subsidiaries. In addition to developing and marketing medical devices, the company conducts research to develop innovative diagnostic and therapeutic methods. The needs of patients and medical research are always the central focus. CVRx Inc specializes in the development and manufacture of implantable electronic devices for the treatment of patients with chronic cardiovascular diseases. The company's main product is the BAROSTIM NEO System, which is CE-certified in Europe. The system consists of two components: an implanted device and an external remote control. The device is surgically placed below the collarbone, and an electrode is inserted into a carotid artery. The remote control is used to regulate the electrical impulses delivered by the device to the carotid artery, activating the baroreflex system. Clinical studies have shown that BAT therapy is effective in lowering systolic blood pressure in patients with severe and persistent hypertension and can also have positive effects on heart failure patients. The company plans to use the BAROSTIM NEO System for other conditions, such as chronic kidney disease or sleep apnea. CVRx also invests in the development of mobile applications and software to support data analysis and patient monitoring. In summary, CVRx Inc is a medical technology company specialized in the development and manufacture of implantable electronic devices. The company is revolutionizing the global market for treatment-resistant hypertension patients with its Baroreflex Activation Therapy (BAT) system. The company focuses on improving patients' quality of life and advancing medical research. In addition to the BAROSTIM NEO System, the company conducts research to develop innovative diagnostic and therapeutic methods. CVRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CVRx stock

Current Assets of CVRx is 90.98 M USD in 2026.

Current Assets of CVRx changed from 129.81 M USD to 90.98 M USD, representing a -29.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets CVRx since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's CVRx historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — CVRx

All Key Metrics — CVRx